Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PP-001
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $11.0 million
Deal Type : Public Offering
Details : PP-001, EyeGate’s lead clinical-stage drug product, is a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase.
Product Name : PP-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2021
Lead Product(s) : PP-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $11.0 million
Deal Type : Public Offering
Lead Product(s) : PP-001
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KIO-101, also known as PP-001, is a next-generation small molecule inhibitor of Dihydroorotate Dehydrogenase. It has demonstrated picomolar potency with a validated mechanism that may offer greater safety and tolerability than DHODH inhibitors currently ...
Product Name : PP-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : PP-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PP-001
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001
Details : PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications.
Product Name : PP-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2021
Lead Product(s) : PP-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EyeGate Pharma Confirms Path Forward with FDA to Develop Combination Product
Details : FDA has granted Aquestive's AQST-108 Fast Track designation, an oral sublingual film formulation that delivers systemic epinephrine in development utilizing proprietary Aquestive PharmFilm ® technologies for treatment of allergic reactions, including an...
Product Name : MoxiGel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2020
Lead Product(s) : Hyaluronic Acid,Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable